FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Machinaton	$ \sim $	20E40	
Washington,	D.C.	20349	

STATEMENT	OF CHANGES	S IN BENEFICIAL	<b>OWNERSHIP</b>

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Stuart Bryan</u>					2. Issuer Name <b>and</b> Ticker or Trading Symbol Fulcrum Therapeutics, Inc. [ FULC ]						(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director 10% Owner					
(Last) C/O FULCF		ERAPEUTICS,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 01/19/2022							X Officer (give title below) See Remarks					
(Street) CAMBRIDO	GE M		02139 (Zip)	4.	4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check App Line)  X Form filed by One Reporting Persor  Form filed by More than One Report												
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			. Transactio ate Month/Day/	Execution Date,		Transaction Disposed Of (D)			Acquired (A) or f (D) (Instr. 3, 4 and 5)		ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
							Code	v	Amount	mount (A) or (D)		Reported Transacti (Instr. 3 a	ion(s)			, ,	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
Derivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any		Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		e s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code V (A) (D) Exercisable Date Title of Shares					Jil(3)									
Stock Option (right to buy)	\$12.69	01/19/2022		A		340,000		(1)	01	/18/2032	Common Stock	340,000	\$0.00	340,00	0	D	

1. This option was granted on January 19, 2022 and is scheduled to vest in equal quarterly installments over four years beginning on the vesting commencement date of January 1, 2022, subject to continued service.

## Remarks:

President & Chief Executive Officer

/s/ Peter Thomson, as attorneyin-fact for Bryan Stuart

01/21/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.